Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Mountain Pacific Investment Advisers Inc. ID

Mountain Pacific Investment Advisers Inc. ID lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 41,671 shares of the medical research company’s stock after buying an additional 620 shares during the period. Thermo Fisher Scientific accounts for approximately 1.4% of Mountain Pacific Investment Advisers Inc. ID’s portfolio, making the stock its 26th largest holding. Mountain Pacific Investment Advisers Inc. ID’s holdings in Thermo Fisher Scientific were worth $22,118,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. grew its position in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. Cedar Mountain Advisors LLC grew its holdings in Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after buying an additional 46 shares during the period. Operose Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after acquiring an additional 75 shares during the period. Financial Connections Group Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $53,000. Finally, Valley National Advisers Inc. raised its stake in Thermo Fisher Scientific by 40.5% during the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of Thermo Fisher Scientific stock opened at $573.60 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The stock has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.44 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The business’s 50 day simple moving average is $573.60 and its 200-day simple moving average is $529.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. HSBC boosted their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. The Goldman Sachs Group increased their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.